Colorectal Cancer Clinical Trial
Official title:
Adenoma Detection Rate With ARC Endocuff Vision Assisted Colonoscopy vs. Standard Colonoscopy in Colorectal Cancer Screening: a Multicenter Randomized Italian Study
In European countries, colorectal cancer (CRC) represents an important public health problem.
It is widely held view that most carcinomas develop from an adenoma-carcinoma progression.
Adenoma detection rate (ADR) is a marker of high quality colonoscopy and it was inversely
associated with the risk of interval colorectal cancer, advanced-stage interval cancer, and
fatal interval cancer after colonoscopy.
Although colonoscopy is considered the gold standard for adenoma detection, it has shown some
limits, so industry has aimed at increasing detection rate of adenomas providing new
technologies, most of witch to detect lesions located in blind spots.
ARC Endocuff Vision (AEV), the second generation of Endocuff, represents a new generation of
these devices, thus assessing the diagnostic sensibility of ARC Endocuff Vision assisted
colonoscopy (EAC) is an interesting challenge.
Aim of the study is to compare ADR of EAC versus standard colonoscopy among FIT positive
subjects in the context of CRC screening programs.
In European countries, colorectal cancer (CRC) represents an important public health problem.
It is widely held view that most carcinomas develop from an adenoma-carcinoma progression.
It has been demonstrated that screening with fecal occult blood test (FOBT) significantly
reduces mortality for CRC. Currently, population-based CRC screening programs using FOBT have
been or are heading towards being implemented in many European countries. Fecal
immunochemical test (FIT) has been adopted by most Italian Regions as the standard screening
test, with total colonoscopy as diagnostic assessment in subjects resulted FIT positive. A
significant impact of FIT-based screening on CRC mortality reduction has been observed in an
Italian region after 10 years from screening implementation. Moreover, two studies carried
out in a Northern-central area of Italy have shown a reduction in CRC incidence in subjects
who attended FIT screening programs as compared to non-attendees.
Increasing colonoscopy quality is critical for the screening impact among population. Adenoma
detection rate (ADR) is a marker of high quality colonoscopy and it was inversely associated
with the risk of interval colorectal cancer, advanced-stage interval cancer, and fatal
interval cancer after colonoscopy. ADR is defined as the proportion of colonoscopies during
which at least one adenoma can be detected. A polish study showed that ADR was an independent
predictor of the risk of interval colorectal cancer after screening colonoscopy. ADR has
shown a direct correlation with: operator experience, cecal intubation, quality of bowel
preparation, patient sedation, endoscope withdrawal time, presence of flat, depressed or
subtle lesions, ability to visualize the proximal side of haustral folds, flexures (blind
spots), rectal valves, and ileocecal valves.
On the other hand, colonoscopy is considered the gold standard for adenoma detection, but it
has shown some limits. Data from colonoscopy studies showed that up to 25% of polyps were
missed during colonoscopy and up to 8% of CRCs occurred within 3 years after a previous
colonoscopy. Moreover, recent studies have shown that cancers post-colonoscopy are most
likely due to missed lesions, rather than being new lesions.
For these reasons, industry has aimed at increasing detection rate of adenomas providing new
technologies, most of witch to detect lesions located in blind spots.
ARC Endocuff Vision (AEV), the second generation of Endocuff, represents a new generation of
these devices, thus assessing the diagnostic sensibility of ARC Endocuff Vision assisted
colonoscopy (EAC) is an interesting challenge.
Previous researches have studied the performance of colonoscope distal attachment devices.
More specifically, a 2016 meta-analysis of more than 5,000 patients demonstrates that,
compared to traditional colonoscopy, the use of an Endocuff device improves ADR without any
adverse effect on procedural efficiency or increased risk of significant adverse events.
Moreover, Facciorusso et al. in 2017 assessed only a modest improvement in ADR by using
distal attachment devices, especially in low-performing endoscopists, while in 2018 Williet
showed, with moderate-quality evidence, an improvement in ADR with EAC without major adverse
events, especially for operators with low-to-moderate ADR.
Second-generation AEV is a soft plastic cap, to be applied on the top of the colonoscopy. The
cap has a propylene-made cylindrical core, with a single row of flexible arms. During the
colon intubation procedure the device is nearly invisible, while in the retraction phase the
arms begin to work, opening up and pulling the colon walls, stretching convoluted tracts.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |